TransMedics Group, Inc. (TMDX) Q4 2024 Annual Earnings

TMDX·Reported February 27, 2025·After market close

TransMedics Group, Inc. reported Q4 2024 revenue of $121.6M, beat analyst consensus of $109.5M by $12.1M. Diluted EPS came in at $0.19, missed the $0.22 consensus by $0.03.

Revenue

$121.6Mbeat by $12.1M

Consensus: $109.5M

Diluted EPS

$0.19missed by $0.03

Consensus: $0.22

SEC Filings

Earnings release8-K not filed yet

Annual report10-K · 0000950170-25-029104

Financial Snapshot

Trailing eight quarters through Q4 2024

View all metrics

Revenue

Net Income

Operating Cash Flow

EPS (Diluted)

Q4 2024 Earnings FAQ

Common questions about TransMedics Group, Inc.'s Q4 2024 earnings report.

TransMedics Group, Inc. (TMDX) reported Q4 2024 earnings on February 27, 2025 after market close.

TransMedics Group, Inc. reported revenue of $121.6M and diluted EPS of $0.19 for Q4 2024.

Revenue beat the consensus estimate of $109.5M by $12.1M. EPS missed the consensus estimate of $0.22 by $0.03.

You can read the 10-K periodic report (0000950170-25-029104) directly on SEC EDGAR. The filing index links above go to sec.gov.